SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
-
25m 59s
-
53sPart 1 | Session 1 Welcome and Introduction
-
10m 23s
-
9m 18sPart 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection
-
12m 18sPart 1 | Session 4 SGLT2 Inhibitors in Cardiology Indications: The Data
-
9m 38sPart 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data
-
14m 38sPart 1 | Session 6 Panel Discussion
-
9m 39sPart 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm
-
8m 1sPart 2 | Session 2 SGLT2 Inhibitors: Safety Considerations
-
7m 39sPart 2 | Session 3 How to Use SGLT2 Inhibitors in Daily Practice
-
6m 58sPart 2 | Session 4 Panel Discussion
-
3m 56sPart 3 | Session 1 Totality of Evidence for the Cardiorenal Patient
-
50m 42sPart 3 | Session 2 Discussion
-
1m 55sPart 4 | Session 1 Welcome and Introduction
-
43mPart 4 | Session 2 KCCQ Score Overview and Discussion
-
1m 11sPart 5 | Session 1 Welcome and Introduction
-
7m 5sPart 5 | Session 2 SGLT2i in the Elderly and Vulnerable Patients
-
27m 15sPart 5 | Session 3 Discussion
-
1m 20sPart 6 | Session 1 Welcome and Introduction
-
11m 2sPart 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits?
-
11m 24sPart 6 | Session 3 Totality of Evidence in Heart Failure
-
11m 20sPart 6 | Session 4 Trial Results Coming Out Soon
-
10m 55sPart 6 | Session 5 Heart Failure Guidelines
-
14m 37sPart 6 | Session 6 Panel Discussion
-
1m 1sPart 7 | Session 1 Welcome and Introduction
-
17m 18s
-
11m 29sPart 7 | Session 3 Panel Discussion
-
11m 8sPart 8 | Session 1 Welcome and Introduction
-
6m 43sPart 8 | Session 2 Soloist Trial Overview
-
36m 32sPart 8 | Session 3 Discussion
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
Educational Objectives
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
Target Audience
- Cardiologists
- Nephrologists
- Endocrinologists
More from this programme
Part 2
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Part 3
Meet The Expert: Implications for Clinical Practice - Breakout 1
Part 4
Meet The Expert: Implications for Clinical Practice - Breakout 2
Part 5
Meet The Expert: Implications for Clinical Practice - Breakout 3
Part 6
State of the Art 2
Part 7
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Part 8
Meet The Expert: Implications for Clinical Practice - Breakout 4
Part 9
Meet The Expert: Implications for Clinical Practice - Breakout 5
Part 10
Meet The Expert: Implications for Clinical Practice - Breakout 6
Faculty Biographies
Paola Fioretto
Professor of Medicine
Prof Paola Fioretto is a Professor of Medicine at University of Padova, Padua, IT.
Her research interest includes the effects of glucose lowering therapies on the development and progression of diabetic kidney disease.
Prof Fioretto started her research on renal physiology in diabetes and during her PostDoc Research Fellowship at the University of Minnesota, she devoted her interest to renal structure and ultrastructure in diabetes.
Katherine Tuttle
Executive Director of Research
Dr Katherine R Tuttle, is Professor of Medicine in the Nephrology Division and Kidney Research Institute at the University of Washington, US. Executive Director for Research at Providence Inland Northwest Health, and a Co-Principal Investigator for the ITHS. Her major research interests are in the areas of clinical and translational science and precision medicine for diabetic kidney disease, chronic kidney disease, diabetes, and hypertension. Dr Tuttle has led a major patient registry as well as clinical trials in these fields that have delivered breakthrough therapies to prevent kidney failure and cardiovascular events.